Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques

Dry powder inhaler, Nanopharm, OINDPs

03 Dec 2025

Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques

Download the Microstructural Characterization of Dry Powder Inhaler Formulations Publication

Articles

Intranasal Oligonucleotide Delivery: Nanopharm & Aptar Pharma Data

Nanopharm and Aptar Pharma present new data at IPAC-RS NIF 2026 proving Antisense Oligonucleotide (ASO) biologics can be nasally delivered intact

September 18, 2026 No Comments

Articles

The SmartTrack® validation study. Changing the game in regulatory approvals for generic OINDPs

Key takeaways from ISAM 2026: Nanopharm’s Lucas Silva on inhaled biologics, digital health and regulatory science in nasal and pulmonary drug delivery.

September 10, 2026 No Comments

Articles

ISAM 2026: Looking Forward to the Next Chapter for Inhaled and Nasal Drug Delivery

Key takeaways from ISAM 2026: Nanopharm’s Lucas Silva on inhaled biologics, digital health and regulatory science in nasal and pulmonary drug delivery.

August 18, 2026 No Comments

About Us

Product Development

Analytical Services

In-Silico Modeling

Regulatory

Nasal

Inhalation

Inhaled Biologics

Generics & Lifecycle Management

Resources

03 Dec 2025

Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques

Related Posts

Intranasal Oligonucleotide Delivery: Nanopharm & Aptar Pharma Data

The SmartTrack® validation study. Changing the game in regulatory approvals for generic OINDPs

ISAM 2026: Looking Forward to the Next Chapter for Inhaled and Nasal Drug Delivery